Celltrion's Biosimilar Clinical Evidence Heavily Weighted By Ex-US Data
Executive Summary
On FDA's advice, Inflectra sponsor conducted three-way pharmacokinetic bridging study to justify relevance of clinical comparative efficacy data using European version of Remicade.
You may also be interested in...
Pfizer Excludes EU Biosimilar Experience From US Epoetin Application
Even though US product has same cell line and drug product formulation as EU-approved Retacrit, Hospira subsidiary did not bridge to it in its US biosimilar application, meaning US FDA could not consider EU safety and efficacy experience.
Pfizer Excludes EU Biosimilar Experience From US Epoetin Application
Even though US product has same cell line and drug product formulation as EU-approved Retacrit, Hospira subsidiary did not bridge to it in its US biosimilar application, meaning US FDA could not consider EU safety and efficacy experience.
Biosimilar Sponsors May Be Going Overboard On Clinical Data, FDA Says
Studying multiple indications 'not the right way to approach biosimilars,' agency says; Amgen conducted more studies than needed for its proposed Humira biosimilar to enhance patient and physician confidence.